Pfizer Inc ((PFE)) announced an update on their ongoing clinical study.
Don’t Miss TipRanks’ Half-Year Sale
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Pfizer Inc. is conducting a Phase 3 clinical study titled AN INTERVENTIONAL, EFFICACY, AND SAFETY, PHASE 3 RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY WITH AN OPEN-LABEL EXTENSION TO INVESTIGATE RIMEGEPANT IN MIGRAINE PREVENTION IN ADOLESCENTS 12 TO LESS THAN 18 YEARS OF AGE WITH CHRONIC MIGRAINE. The study aims to evaluate the efficacy and safety of rimegepant, a dissolvable tablet, in preventing migraines in adolescents who experience frequent migraine attacks. This research is significant as it targets a younger demographic often affected by chronic migraines.
The intervention being tested is rimegepant, an orally disintegrating tablet designed to prevent migraine attacks. Participants will receive either rimegepant or a placebo every other day during the study’s initial phase.
The study follows a randomized, double-blind, placebo-controlled design with a parallel intervention model. It employs quadruple masking, meaning that the participant, care provider, investigator, and outcomes assessor are all blinded to the treatment allocation. The primary purpose of the study is prevention.
The study began on November 15, 2024, and the last update was submitted on July 8, 2025. These dates are crucial as they mark the study’s progress and provide a timeline for potential results and conclusions.
The outcome of this study could significantly impact Pfizer’s stock performance and investor sentiment, especially if rimegepant proves effective in a younger population. This could position Pfizer favorably against competitors in the migraine treatment market.
The study is ongoing, and further details are available on the ClinicalTrials portal.